Dr. Pacheco on Frontline Therapy for Patients With EGFR-Mutant NSCLC

Video

Jose M. Pacheco, MD, an assistant professor of medicine/medical oncology at the Colorado University School of Medicine, discusses frontline therapy for patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Jose M. Pacheco, MD, an assistant professor of medicine/medical oncology at the Colorado University School of Medicine, discusses frontline therapy for patients with EGFR-mutant non—small cell lung cancer (NSCLC).

The established genetic alterations for which physicians have approved targeted therapies include EGFR activating mutations, ALK fusions, ROS1 fusions, and BRAF V600E mutations, says Pacheco. Data from the FLAURA study presented within the past year suggested that first-line osimertinib (Tagrisso) provides a progression-free survival (PFS) benefit for patients with traditional EGFR activating mutations, such as exon 19 deletions and EGFR L858R point mutations in exon 21. The PFS benefit for osimertinib compared with gefitinib (Iressa) or erlotinib (Tarceva) was 19 months versus 10 months, notes Pacheco.

From a population-based standpoint, it makes more sense to give osimertinib first as opposed to sequencing EGFR inhibitors. If 100 patients are treated with osimertinib, the median PFS could be 19 months based on the trial data. If 100 patients are treated with gefitinib or erlotinib, the median PFS would be approximately 10 months, and only 50% to 60% of those patients would be eligible for sequencing with osimertinib. As high as 40% of patients may not reach second-line therapy, so it is important to give patients the therapy with the most impact upfront, adds Pacheco.

Recent Videos
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Linda Marbán, PhD, the CEO of Capricor Therapeutics
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
© 2025 MJH Life Sciences

All rights reserved.